MedTrace Logo

Treatment of Intimate Partner Violence and Substance Abuse in a Substance Abuse Treatment Facility

NCT00847873 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-11-05

No results posted yet for this study

Summary

Intimate partner violence is a significant societal problem. There is considerable evidence that a strong relationship between the use of alcohol and other drugs and intimate partner violence exists. Besides, a few studies indicate that reducing substance use may have a positive impact on IPV. Therefore, in this study, patients in substance abuse treatment for the use of alcohol, cannabis or cocaine who also admit to perpetrating intimate partner violence will be randomly assigned to either cognitive behavioral therapy addressing substance abuse combined with treatment for offenders of intimate partner violence or substance abuse treatment alone.

Conditions

Interventions

BEHAVIORAL

substance abuse/domestic violence treatment

This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse

BEHAVIORAL

Cognitive behavioral therapy addressing substance abuse

This intervention is comprised of 16 sessions of cognitive behavioral therapy addressing substance abuse.

Sponsors & Collaborators

  • VU University of Amsterdam

    lead OTHER

Principal Investigators

  • Paul M. Emmelkamp, PhD. · University of Amsterdam

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2012-12-31
Completion
2013-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00847873 on ClinicalTrials.gov